REGEND001による肺拡散機能障害を伴う慢性閉塞性肺疾患(COPD)の治療
肺拡散機能不全を伴う慢性閉塞性肺疾患(COPD)の治療のためのREGEND001自家療法製品の多施設、無作為化、単一盲検、プラセボ並行対照研究
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- China-Japan Friendship Hospital
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国
- The Southwest Hospital of AMU
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha、Hunan、中国、410008
- Xiangya Hospital of Central South University
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215006
- The First Affiliated Hospital of Soochow University
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- The First Affiliated Hospital of Nanchang University
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- Shanghai East Hospital
-
Shanghai、Shanghai Municipality、中国
- Zhongshan Hospital affiliated to Fudan University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, aged 40 to 75 at the time of signing informed consent.
- Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD).
- The ratio of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)FEV1/FVC is < 70% after inhalation of bronchodilators.
- The diffusion function of carbon monoxide (DLCO) is ≥ 20% and < 80% of the predicted value at screening.
- Tolerated to pulmonary function tests.
- Tolerated to bronchoscopy
- Voluntary to sign the informed consent, coordinated to finish the trial-related procedures and tests, and capable of recording or stating the change of disease condition in a relatively complete manner.
Exclusion Criteria:
-
Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);
-
Subjects with a positive result for any of the following tests at screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. But except the followings:
- Hepatitis B virus carriers (only HBsAg positive without any hepatitis symptom or sign, and all liver function tests present normal results or abnormal markers without clinical significance by the assessment of investigators);
- Cured hepatitis C patients (negative in HCV ribonucleic acid (RNA) test);
-
Subject with assessed survival time of < 1 year by investigators at screening;
-
Subject with malignant tumors or a history of malignant tumors at screening;
-
Subject with infections in lung or other sites, requiring intravenous drug treatment within a week prior to screening;
-
Subject with more than 4 moderate-to-severe AECOPD, resulting in hospitalization within a year prior to screening;
-
Subject with one or more pathogenetic or serologic findings of the novel coronavirus infection, or symptoms of suspected infection within 6 weeks prior to screening;
-
Subject with a history of invasive or noninvasive mechanical ventilation within 4 weeks prior to screening;
-
Subject who has taken prednisone tablets orally at a dose of ≥ 20 mg/day (or equivalent amount of other oral corticosteroids) within 4 weeks prior to screening;
-
Subject with major lung diseases other than COPD by assessment of investigators at screening;
-
Subject with severe systemic diseases other than lung within 6 months prior to screening and assessed to be inappropriate to participate in this trial by investigators;
-
Subject with severe anemia or poorly controlled granulocyte deficiency, thrombocytopenia by assessment of investigators;
-
Subject with abnormal coagulation and assessed to be negative for the safety of fiberoptic bronchoscopy operations at screening;
-
Subject requiring long-term anticoagulation therapy of using antiplatelet coagulant therapeutic agents and disable to discontinue their medications 1 week prior to cell collection and cell infusion as assessed by investigators;
-
Subject with a risk of suicide, a history of mental illness or a history of epilepsy at screening;
-
Subject with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening;
-
Subject participated in other clinical trials with interventions within 3 months prior to screening;
-
Investigators, co-investigators, research coordinators, employees of research participants or research centers, or their family members;
-
Any circumstance considered to probably increase the risk of patients or interfere with the clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Placebo |
Transplantation of Placebo |
|
実験的:REGEND001 cell therapy
REGEND001 cell therapy |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Responsive rate (RR)
時間枠:12 weeks after treatment, 24 weeks after treatment
|
Ratio of subjects responsive to the treatment. Subject is considered to be responsive to the treatment as (1) the lung diffusing capacity for carbon monoxide (DLCO) improvement meets MCID (minimal clinically important difference) at 12 or/and 24 weeks after therapy; and (2) mean of DLCO at 12 and 24 weeks is no less than the baseline value. MCID of DLCO improvement is 1.1 ml/min/mmHg (0.37 mmol·min -1·kPa-1) or 11% for measured value compared to baseline . |
12 weeks after treatment, 24 weeks after treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change of lung diffusing capacity for carbon monoxide (DLCO) from baseline
時間枠:Within 52 weeks after treatment
|
DLCO is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin. |
Within 52 weeks after treatment
|
|
Change of the alveolar volume (VA) from baseline
時間枠:Winthin 52 weeks after treatment
|
Alveolar ventilation is the exchange of gas between the alveoli and the external environment. It is the process by which oxygen is brought into the lungs from the atmosphere and by which the carbon dioxide carried into the lungs in the mixed venous blood is expelled from the body. |
Winthin 52 weeks after treatment
|
|
Change of images of lung by high resolution computed tomography (HR-CT) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
HR-CT images of lung will be analyzed to indicate the change of pulmonary structure. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of forced vital capacity (FVC) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
FVC is the full amount of air that can be exhaled with effort in a complete breath. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of forced expiratory volume in one second (FEV1) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
FEV1 is the volume of breath exhaled with effort in one second. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The FEV1/FVC is a ratio that reflects the amount of air you can forcefully exhale from your lungs. It's measured by spirometry, a test used to evaluate lung function. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of the diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.Since DLCO is affected by the amount of inhaled gas and lung volume, the subject's alveolar ventilation (VA) is also considered when evaluating diffusion function to exclude the effect of lung volume on diffusion volume. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of 6-minute-walk test (6MWT) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of modified medical research council (mMRC) dyspnea scale from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
It is a questionnaire to evaluate how breathlessness impacts daily activities. According to the degree of activity impacted by shortness of breath, mMRC results are divided into 0-4 grades. Grade 0 means no breathlessness except on strenuous exercise; grade 1 means shortness of breath when hurrying on the level or walking up a slight hill; grade 2 means walking slower than people of same age on the level because of breathlessness or having to stop to catch breath when walking at their own pace on the level; grade 3 means stoping for breath after walking ∼100 m or after few minutes on the level ground; and grade 4 means too breathless to leave the house, or breathless when dressing or undressing. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Change of chronic obstructive pulmonary disease Assessment Test (CAT) from baseline
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
The CAT is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT scale includes a total of 8 items, 0~5 points for each item. The total score ranges 0~40 points. Score of 0-10 points indicates slight impact; Score of 11-20 points indicates medium impact: Score of 21-30 points indicates serious impact; Score of 31-40 points indicates very serious impact. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Annual frequency of exacerbations
時間枠:1 year after treatment
|
Frequency of exacerbations all through the year. A lower frequency means improvement of disease. |
1 year after treatment
|
|
Symptoms, physical examination
時間枠:Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal physical examination findings. |
Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
12-lead ECG
時間枠:4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal 12-lead Electrocardiogram (ECG). |
4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Blood routine
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal laboratory test results. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Urine routine
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal laboratory test results. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Blood biochemistry
時間枠:Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal laboratory test results. |
Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Function of blood clotting
時間枠:Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
Number of cases with abnormal function of blood clotting. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Carcinoembryonic antigen (CEA)
時間枠:Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
CEA is a tumor marker used for early diagnosis of lung cancer. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Neuron-specific enolase (NSE)
時間枠:Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
NSE is a tumor marker significantly elevated in small cell lung cancer. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Cytokeratin-19-fragment (CYFRA21-1)
時間枠:Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
|
Squamous cell carcinoma antigen (SCC)
時間枠:Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
SCC is a specific marker for lung squamous cell carcinoma.Tumor markers are monitored to assess the safety. |
Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment
|
協力者と研究者
スポンサー
協力者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- REGEND001-COPD-201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。